Agoracom Blog Home

Posts Tagged ‘MMJ’

Namaste $N.ca Announces Updates to NamasteMD Patient Acquisition Portal and Appointment of Baran Dilaver as Interim COO $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:00 AM on Monday, May 14th, 2018

Namaste large new

  • Announced the integration of several critical updates to the Company’s online patient acquisition tool, NamasteMD Inc.
  • Company’s revolutionary mobile app, which is available on desktop, Apple IOS and Android devices, has allowed Namaste to accelerate patient growth at a rate that exceeds any industry peers and at significantly lower cost per patient

VANCOUVER, British Columbia, May 14, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce the integration of several critical updates to the Company’s online patient acquisition tool, NamasteMD Inc. (“NamasteMD”). NamasteMD, which is the Company’s revolutionary mobile app, which is available on desktop, Apple IOS and Android devices, has allowed Namaste to accelerate patient growth at a rate that exceeds any industry peers and at significantly lower cost per patient. NamasteMD is presently ranked as the #2 Medical application in the Canadian Apple Store. NamasteMD provides a simple digital platform for patients to acquire medical cannabis documentation from the comfort of their home. Since its initial launch, the Company has acquired over 2,000 patients exclusively through organic growth without any paid advertising. The Company believes that the recent updates to the app will allow Namaste to fully deploy its marketing strategy and accelerate growth in what the Company believes will soon be Canada’s largest database of medical cannabis patients.

With this release patients now have a more streamlined and reliable video experience, enabled by our trusted partner Twilio. This release also includes stability and performance improvements, including a fix for a bug that was preventing a small percentage of our users from logging in. The Company will focus on continued updates to increase the acceleration rate of its patient database through organic and paid advertising channels.

Additionally, the Company would like to announce that co-founder Kory Zelickson is transferring roles to become Vice President of Business Development and Investor Relations, and that Baran Dilaver will be appointed as the Company’s interim Chief Operating Officer. With the Company’s rapid expansion, Kory will focus on the growth of the Company in the areas of business development, strategic partnership and in investor relations and hand-off operations to Baran Dilaver, who has many years of experience in operations. This strategic decision will allow both Kory and Baran to excel in each of their respective areas to further propel the growth of the Company. Mr. Baran Dilaver has extensive experience in running companies and for the past three months, Baran Dilaver has been focused on improving Namaste’s operations and organizing its various business divisions. The Company welcomes Baran in joining as Interim COO and believes that these changes will provide further value to its shareholders. Upon his appointment, Baran Dilaver commented: “I am thrilled to have such a critical role in shaping Namaste’s future, and I am in a great position to lead the recruitment of a world class COO to hand over some of the initiatives I started here with the operations and finance teams.”

About Baran Dilaver

Baran is an entrepreneur, creator, and an accomplished executive.  He launched several well-known brands worldwide and conceived and developed over 80 products.  Baran is the founder of FutureScape, a technology focused product design and branding company and recently, as the COO and CMO at Firefly Vapor, he created and implemented business strategies that established Firefly as one of the most admired brands in the cannabis industry.  Prior to Firefly, Baran Dilaver was the CEO of United Brands, a leading food technology company based out of San Francisco. He is a speaker in conferences like Tech Open Air Berlin, CannaTech, and European Communications Summit.  He was a scholar athlete at UC Berkeley and studied Economics.  He loves kitesurfing and snowboarding around the world and building large-scale art installations at Burning Man.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We’re very pleased to have had major updates approved to the NamasteMD platform. I believe that NamasteMD provides the Company with a competitive edge in being the first company in Canada to fully digitize patient acquisition. At a cost of only $60 per patient, Namaste is able to acquire patients at a much lower cost than our peers who require the use of physical clinics or doctors to acquire patients. In a very short period of time we have managed to acquire over 2,000 patients organically with zero spend on marketing or promotion. At this point of the business cycle we now feel that the platform is ready for full launch and anticipate an even more significant acceleration of growth over the next several months through a strategic marketing campaign.

Additionally, I’m very pleased to have Kory focus on his areas of expertise in business development and investor communications where he brings major value to the Company. We have been continuously growing as a company and Kory has filled in as COO, but we have now decided to have each team member focus exclusively in their areas of expertise. The investor relations and business development role is very important to the Company and Kory is best fit for this role. We are also very pleased to be bringing on Baran Dilaver as interim COO who has many years of experience in the industry and as someone who has developed a deep level of understanding of Namaste’s global operations. Moving forward we are in a prime position to leverage an amazing management team and innovative technology to advance as a global leader in all things cannabis.”

About Namaste Technologies Inc.

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer with a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The TSXV has neither reviewed nor approved the contents of this press release.

Namaste $N.ca $NXTTF Signs Exclusive Drop-Shipping Agreement With Ample Organics Enabling Ample’s Licensed Producer Customers to Sell Vaporizers and Accessories $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:49 AM on Monday, May 7th, 2018

  • Signed an exclusive drop-shipping supply agreement with Ample Organics Inc.
  • Ample Organics is Canada’s leading seed-to-sale software platform, currently used by the majority of Canada’s licensed producers of medical cannabis
  • Namaste will connect its cannabis hardware and accessory platform via API integration with Ample Organics’ system

VANCOUVER, British Columbia, May 07, 2018 — Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that the Company has signed an exclusive drop-shipping supply agreement (the “Agreement”) with Ample Organics Inc. (“Ample Organics”). Ample Organics is Canada’s leading seed-to-sale software platform, currently used by the majority of Canada’s licensed producers of medical cannabis (“LPs”). Under the terms of the Agreement, Namaste will connect its cannabis hardware and accessory platform via API integration with Ample Organics’ system. This will allow each of Ample Organics’ LP customers to have instant access to a large variety of devices and accessories available for purchase during checkout. The Agreement will provide added value for Ample Organics customers by offering their patients industry-leading products. Namaste is proud to have this unique opportunity in partnering with Canada’s most innovative seed-to-sale software company and this Agreement clearly demonstrates Namaste’s continued focus on achieving technological development for the cannabis industry.

Key Terms of the Agreement

  • Namaste will supply Ample Organics customers with access to the Company’s full range of vaporizers and accessories through an API integration, as the exclusive drop-shipping supplier to Ample Organics.
  • Namaste will have first right of refusal to supply new products as requested by Ample Organics, or its customers, for drop-shipping through the API integration.
  • In the event that Namaste decides not to carry a new product or cannot source such product within 30 days, Ample Organics will be granted the right to offer the new product using drop-shipping through a 3rd party supplier.
  • Each order will be submitted electronically via API integration that will also provide live access to tracking information, inventory and shipping data.
  • Namaste will be responsible, at its cost for all product support, returns and warranty claims.
  • Unless Namaste advises otherwise, solely due to pricing restrictions from the product manufacturers, Ample Organics and its customers shall agree to set the prices for the Products at a Minimum Advertised Price (MAP), to be specified by Namaste for each product.

Namaste’s partnership with Ample Organics represents a unique opportunity to provide virtually hundreds of thousands of medical cannabis patients with access to a variety of high-quality vaporizers, which research has shown is a far superior and healthier way to consume medical cannabis. This agreement further demonstrates Namaste’s commitment to the medical cannabis patients of Canada, and in ensuring that they have easy and affordable access to the best cannabis hardware products on the market.

The Agreement represents an important step for Namaste and is accretive in nature, as it will provide immediate, low-overhead revenue for both Namaste and Ample Organics. The Company will now focus its efforts on completing the integration with Ample Organics as soon as possible and will continue to explore further opportunities that have the potential to bring value to Namaste, its partners, and the entire cannabis market.

Management Commentary

John X. Prentice, President and CEO of Ample Organics comments; “This partnership represents a substantial value-add for Ample Organics’ clients and their patient customers. It will simplify inventory management and fulfillment for LPs, while ensuring that medical cannabis patients across the country have access to a substantial catalogue of vaporizers and cannabis accessories at great prices. We are excited to continue the development of our relationship with Namaste and look forward to advancing the industry in new and innovative ways together.”

Sean Dollinger, President and CEO of Namaste comments; “We are very proud to be partnered with Ample Organics on this project. It’s been very rewarding to collaborate with the management team, on what we believe is an important initiative for all those involved, most importantly of which are the medical cannabis patients of Canada. We are incredibly excited to be associated with Ample Organics and to have the opportunity to provide healthier, more affordable options for medical patients to consume cannabis. Our commitment to developing a platform with easily accessible products and services for the cannabis industry is what inspired the opportunity to work with Ample Organics. We’re looking forward to completing the integration and to further enhancing the patient experience.”

About Ample

Ample Organics is Canada’s leading cannabis business solution, adopted by 75% of the nation’s Licensed Producers. To date, the Ample Organics platform has processed more than 880,000 orders and 16,000,000 grams of cannabis. Ample Organics makes compliance easy by tracking individual plants from seed to consumer and reporting every detail of the growth, production, and sales processes. With Ample Organics, data is collected at the most granular levels, offering insights that can drive business decisions and help to protect public safety. Beyond seed to sale, Ample Organics’ extended suite of products creates a complete ecosystem for cannabis businesses. From easy patient registration to cannabis-exclusive payment solutions, Ample Organics continues to evolve and release new products to provide reliable and compliant solutions for the cannabis industry.

About Namaste Technologies Inc.

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer with a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors,

Sean Dollinger
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au

For more information about Ample Organics, please visit ampleorganics.com or contact:
Peter Slater
VP, Corporate Development
Direct: +1 (416) 262-4175
Email: [email protected]

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Tetra BioPharma $TBP.ca Signs Second Commercialization Deal with Azevedos Industria Farmaceutica, S.A. for the Lead RX product PPP001 $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:24 AM on Friday, May 4th, 2018

Logo tetrabiopharma rgb web

  • Tetra Bio-Pharma Inc. and Azevedos Indústria Farmacêutica, S.A. announced that they have signed a binding term sheet for the marketing and distribution of PPP001 in Portugal
  • Binding term sheet will pave the way towards signing a Definitive Distribution Agreement.
  • Tetra is eligible to receive an upfront payment, milestone payments and will be paid a share of the profits generated by the sales of PPP001 in Portugal.
  • Azevedos will also be responsible for registering the product, as well as all marketing and distribution in Portugal

OTTAWA, May 04, 2018 – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), and Azevedos Indústria Farmacêutica, S.A. announced that they have signed a binding term sheet for the marketing and distribution of PPP001 in Portugal. This binding term sheet will pave the way towards signing a Definitive Distribution Agreement.

Tetra is eligible to receive an upfront payment, milestone payments and will be paid a share of the profits generated by the sales of PPP001 in Portugal. Azevedos will also be responsible for registering the product, as well as all marketing and distribution in Portugal.

“We are honored to partner with Azevedos, a company established in 1775, rich in tradition, and a major player in the Portuguese pharmaceutical market. This Partnership deal provides Tetra with its foray into the European market.” stated Dr. Guy Chamberland M.Sc., Ph.D., Interim CEO and Chief Scientific Officer.

“These partnerships are very important for Azevedos Indústria Farmacêutica and mean that international entities recognize our history, values, work and our technology know-how. Although having a long past, Azevedos is a pharmaceutical company turned to the future and focused on new challenges”, says Thebar Miranda, CEO of Azevedos Indústria Farmaceutica, S.A.

About PPP001 
On April 4, 2018, Tetra officially started the Phase 3 trial for PPP001 indicated for terminal stage cancer patients with a goal to improving the quality of life of these patients as well as minimizing their pain. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

About Azevedos Indústria Farmacêutica, S.A
Azevedos Group is a two-century Portuguese pharmaceutical brand, whose wide scope of activity ranges from development to distribution, leading manufacturing and exports to more than 60 regulated countries worldwide. Azevedos owns more than 300 MAs for the most relevant therapeutic areas covering all technology forms manufactured at its state of the art plant holding the most recognized certifications.

About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. Tetra Bio-Pharma is currently developing a pipeline of five cannabinoid-based products using different delivery systems such as smokable pellets, oral tablets, eye drops and topical ointments.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact:
Tetra Bio-Pharma Inc.
Dr Guy Chamberland, interim CEO and CSO
[email protected]
514-220-9225

Robert (Bob) Bechard, MBA, MSc., BA,
Vice-President Finance and Business Development
[email protected]
514-817-2514

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514-840-7990 M: 1 514-232-1556

Namaste $N.ca Receives Final Approval to List on TSX Venture Exchange $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:36 AM on Tuesday, May 1st, 2018

Nlogo

  • Received final approval to list the common shares and warrants of the Company on the TSX Venture Exchange as a Tier 1 issuer
  • Common shares and warrants of the Company will be delisted from the Canadian Securities Exchange at the close of trading on May 1, 2018 and listed on the TSXV at the opening of trading on May 2, 2018

VANCOUVER, British Columbia, May 01, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that the Company has received final approval to list the common shares and warrants of the Company on the TSX Venture Exchange (“TSXV”) as a Tier 1 issuer. The common shares and warrants of the Company will be delisted from the Canadian Securities Exchange at the close of trading on May 1, 2018 and listed on the TSXV at the opening of trading on May 2, 2018. The Company’s common shares will continue to trade under the symbol “N” and its warrants will continue to trade under the symbol “N.WT.” The Company believes that listing on the TSXV will provide Namaste and its shareholders with many advantages, including greater visibility and enhanced market access for Canadian and international investors.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to have received final approval to list on the TSXV as a Tier 1 issuer. We’re proud to have reached a point where the Company will gain more exposure through a larger market and to join many of our peers on the TSXV. We’d like to thank our shareholders and management team for their continued support. This is certainly an exciting day in the history of Namaste and we look forward to a bright future.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 24 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., which operates a medical cannabis “sales-only” license under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”), is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in ecommerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

 

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com

namastevapes.ca

everyonedoesit.ca

namastevaporizers.co.uk

everyonedoesit.co.uk

australianvaporizers.com.au

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Namaste $N.ca $NXTTF Announces Record-Breaking Quarterly Sales of $5.6M Representing a 195% Quarter-Over-Quarter Increase and Over 1,600 Medical Cannabis Patients $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 10:09 AM on Monday, April 30th, 2018

Nlogo

  • Sales for the second quarter of 2018 were $5.6M,
    • representing a $3.7M or 195% increase quarter-over-quarter 
  • Gross profit for the second quarter of 2018 was $1.9M,
    • representing a $1.2M or 150% increase quarter-on-quarter
  • Over 1,600 Medical Cannabis Patients Acquired To-Date Through NamasteMD

VANCOUVER, British Columbia, April 30, 2018 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) is pleased to announce the filing of its unaudited quarterly financial statements, management’s discussion and analysis and certification of the quarterly filings for the second quarter of fiscal 2018. The statements for the period can be accessed on the Company’s SEDAR profile at www.sedar.com.

The Company’s sales for the second quarter of 2018 were $5.6M, representing a $3.7M or 195% increase quarter-over-quarter.  Gross profit for the second quarter of 2018 was $1.9M, representing a $1.2M or 150% increase quarter-on-quarter. For the first six months of the year, the Company had sales of $10.6M, representing a $6.6M or 165% increase year-on-year. Gross profit for the first six months of 2018 was $3.6M, representing a $2.1M or 140% increase year-over-year. The gross profit increase relates primarily to the growth in revenue outside the United States.

Namaste’s management team is extremely encouraged by the financial position of the Company and anticipates seeing accelerated growth in Q3 and Q4 of 2018. The Company has been focused on launching many new initiatives, the most significant of which is the addition of medical cannabis sales through the Company’s wholly-owned subsidiary, Cannmart Inc. (“Cannmart”). Namaste will focus on expanding its international platform and in developing new opportunities domestically and abroad.

The Company has also seen a significant impact on Canadian operating costs for its hardware business, correlated to the integration of Namaste’s platform with Greenlane Canada Inc., whereby inventory management and order processing are fulfilled by Greenlane. The integration with Greenlane has completely removed all inventory costs and has also streamlined operations. The Company anticipates further cost reductions by pursuing similar strategic partnerships which bring long-term value to the Company and its shareholders.

Namaste’s management team is now highly focused on patient acquisition through the Company’s innovative telemedicine application, NamasteMD. To date, the company has acquired over 1,600 patients, all of which were driven organically through Namaste’s platform. The Company’s marketing team will be working through various marketing channels to further accelerate patient growth while expanding its clinic team in order to accommodate anticipated demand. With strong initial results on patient acquisition costs and conversion rates, Namaste believes that it will be able to acquire medical patients faster and at a lower cost than any of its industry peers.

The Company is also looking forward to trading on the TSX Venture Exchange (“TSXV”) as a Tier 1 issuer, which will provide Namaste and its shareholders with many advantages, including greater visibility and enhanced market access for Canadian and international investors.

Quarterly Financial Highlights

  • The majority of revenues were generated by several key markets. The top five countries generated 85% of revenues for the second quarter of 2018 compared to 84% for the second quarter of 2017. The table below depicts gross revenues by country.
Revenues by country
For three months ended For six months ended
Country February 28,
2018
February 28,
2017
February 28,
2018
February 28,
2017
United Kingdom $1,346,193.00 $737,946.00 $2,580,175.81 $1,285,227.00
Australia $1,234,429.00 $91,371.00 $2,650,200.00 $170,254.62
United States of America $1,140,217.00 $525,518.00 $1,817,768.84 $1,437,529.00
Brazil $380,879.00 $100,591.00 $735,322.92 $202,514.00
Canada $678,815.00 $78,985.00 $1,034,446.63 $159,223.00
Germany $287,878.00 $32,660.00 $550,487.86 $56,097.00
New Zealand $71,714.00 $75,149.00 $176,197.59 $209,317.00
Ireland $36,902.00 $51,759.00 $98,722.14 $87,264.00
Israel $94,160.00 $26,367.00 $157,004.13 $48,603.00
Other $362,643.00 $186,760.00 $764,614.08 $338,265.38
Total $5,633,830.00 $1,907,106.00 $10,564,940.00 $3,994,294.00
  • Operating costs for the second quarter of 2018 were $5.5M compared to $2.4M for the second quarter of 2017. The $3.1M quarter-over-quarter increase in operating costs is primarily due to non-cash charges of $1.5M, which included share-based compensation, amortization of intangible assets, and depreciation.
  • Selling expenses for the second quarter of 2018 were $1.7M compared to $0.6M for the second quarter of 2017, representing an increase of $1.1M quarter-on-quarter. The increase was due in part to an increase in advertising expenses of $0.6M and consulting expenses of $0.5M. Advertising expenses related to online search services as well as other online promotional and social media tools utilized by the Company to generate sales. These costs further represent the Company’s significant investment into search engine optimization and its ongoing customer acquisition strategy. Consulting expenses relate to compensation amounts paid to various companies and individuals for marketing, order fulfillment, customer service activities, e-commerce product development, back-office e-commerce support and sales commissions. The increase in consulting fees is primarily related to information technology in order to develop current and new revenue channels.
  • Administration expenses for the second quarter of 2018 were $3.5M compared to $1.8M for the second quarter of 2017, representing an increase of $1.7M quarter-over-quarter. The increase is primarily due to share-based compensation of $1.3M and increases in merchant fees and professional fees.
  • Other expenses for the second quarter of 2018 were $0.3M compared to approximately $nil for the second quarter of 2017, representing an increase of $0.3M quarter-over-quarter. The increase was primarily due to the amortization of intangibles of $0.2M, which relates to the amortization of the customer list from the acquisition of Australian Vaporizers.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “We are very pleased with the Q2 financials. The Company continues to see quarter-on-quarter growth at a rapidly accelerating rate, even after having divested our US assets. Our management team remains focused on ramping up patient acquisition through NamasteMD, and we anticipate launching medical cannabis sales through Cannmart in the near future. Namaste will continue to pursue and develop innovative technologies for the cannabis industry. This will be achieved through forming mutually beneficial partnerships and in making strategic investments that bring value to both the Company and the cannabis sector as a whole. We feel that the Company is now positioned for significant growth going forward which will be achieved by accelerating patient acquisition, adding medical cannabis sales to our platform and by implementing new technologies to an already impressive platform.”

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 24 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., which operates a medical cannabis “sales-only” license under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”), is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors
“Sean Dollinger”
Chief Executive Officer Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Tetra Bio-Pharma $TBP.ca Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel #MMJ #Marijuana $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:14 AM on Tuesday, April 24th, 2018

Logo tetrabiopharma rgb web

  • Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd
  • Signing of a Definitive Distribution Agreement is expected to follow shortly
  • PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription

OTTAWA, ONTARIO–(April 24, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), announced today that the Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd., a leading pharmaceutical company. The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

This first international market commercialization agreement represents a significant milestone and a validation of Tetra Bio-Pharma’s business model with a leading Israel-based pharmaceutical company. Israel, like Canada, is considered one of the world leaders in the production and development of cannabinoid-based products. Kamada is a company with two FDA-approved products and an Israeli-based distribution segment that has demonstrated continued growth. Tetra Bio-Pharma intends to work closely with Kamada as PPP001 advances towards regulatory approval and commercial launch in Israel.

Under the terms of the anticipated final agreement, Kamada will be responsible for registering the product, as well as all marketing and distribution, in Israel. Tetra will be eligible to receive certain milestone payments and an undisclosed percentage of the sales of PPP001 generated by Kamada in Israel.

About PPP001 

On April 4, 2018, Tetra Bio-Pharma officially started the Phase 3 trial for PPP001 indicated for terminal stage cancer patients with a goal to improving the quality of life of these patients as well as minimizing their pain. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. Tetra Bio-Pharma is currently developing a pipeline of five cannabinoid-based products using different delivery systems such as smokable pellets, oral tablets, eye drops and topical ointments. More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Robert (Bob) Béchard
Vice President Finance and Business Development
[email protected]
M: +1 514 817-2514

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: +1 514 840 7990
M: +1 514 232 1556

The medical #marijuana industry is about to get much bigger, CannTrust CEO says $N.ca $NXTTF $TBP.ca $MCOA $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 12:11 PM on Friday, April 20th, 2018
  • The ramp up in Canada’s cannabis sector is ongoing
  • Industry estimates of sales eventually adding up to between $5 and $8 billion a year
  • By comparison, Canada produces a little under $3 billion of beer a year and about $1 billion in tobacco products.

April 19, 2018 By Jayson MacLean

Eric Paul

While all eyes are on the launch date for recreational cannabis in Canada —said to come in either late summer or early fall— the medical side of the equation should be getting the attention, as well, because it’s about to get much bigger, says Eric Paul, CEO of licensed producer CannTrust Holdings (TSX:TRST).

The ramp up in Canada’s cannabis sector is ongoing, with industry estimates of sales eventually adding up to between $5 and $8 billion a year. That’s substantial, since by comparison, Canada produces a little under $3 billion of beer a year and about $1 billion in tobacco products.

But while the rec market is getting all the focus, the medical marijuana industry both at home and abroad should be getting its props, since it’s growing by leaps and bounds.

“We’ve been astounded by the growth of the medical marijuana industry in Canada,” Eric Paul, CEO of CannTrust Holdings, tells BNN.

“Roughly ten or 12 per cent of the 80,000 doctors across Canada who could prescribe are prescribing [cannabis], and I would say we’re gaining on that for a number of reasons,” says Paul. “The first being the opiate crisis where doctors are looking for cannabis as a potential first-line therapy for pain management. The second thing is that there is more research coming out; we’re about to announce a couple of major research projects in Canada and one is a major pain management study. As these research projects produce their end result, more doctors are looking at cannabis as an alternate therapy for chronically ill people.”

Statistics Canada has reported that between April and December of last year, the number of clients registered under its Access to Cannabis for Medical Purposes Regulations (ACMPR) has gone from 174,503 to 269,502.

Paul says that CannTrust itself has a 40,000-strong patient base and is looking to jump to 100,000 in 12 months time.

“We’ve had a major expansion in Niagara: a 430,000 sq. ft. state of the art greenhouse which is up and running,” says Paul. “We believe that with that capacity and with the nature of that facility, we’ll be able to supply our current customer demand in the medical market and have sufficient capacity to handle the first generation of recreational demand.”

But aside from Canada’s own growing medical market, the international market is poised to take off in countries like Germany and Australia, and many of the top licensed producers in Canada are now lining up deals outside of Canada.

In March, CannTrust announced that it has entered into a joint venture agreement with a Danish company to grow and sell medical cannabis.

“The industry is globalizing much faster than any of us expected,” says Paul.

“Various countries are going into medical legislation and Denmark is one of those countries that have announced that we’re fully licensed there, we’ll be building a facility there,” he said. “In that country, the government has decided to fund the cost of it for the consumer, via prescription, and they’re willing to fund 100 per cent for people with palliative or end-of-life care and 50 per cent for chronic illness. That will allow those industries to quickly garner market share. Germany is a similar kind of situation and also Australia.”

Source: https://www.cantechletter.com/2018/04/the-medical-marijuana-industry-is-about-to-get-much-bigger-canntrust-ceo-says/

Marijuana Company of America’s $MCOA Joint Venture Completes Set-up of 7,000 Sq. Ft. Greenhouse Facility in Washington State $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:14 AM on Wednesday, April 18th, 2018

15233 mcoa

  • Completed the construction of three greenhouses totaling 7,000 square feet
  • Represents the completion of more than 23% of the total 30,000-square-foot cultivation facility

Escondido, California–(April 18, 2018) – MARIJUANA COMPANY OF AMERICA INC.  (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that its joint venture project, BV-MCOA Management, LLC, has completed the construction of three greenhouses totaling 7,000 square feet. This represents the completion of more than 23% of the total 30,000-square-foot cultivation facility.

The Company entered into the joint venture agreement with Bougainville Ventures, Inc. on March 16, 2017, and subsequently arranged for $800,000 funding for the purchase of the land and the construction of the greenhouses. Transfer of ownership of the property to the joint venture is pending completion of the final subdivision of the property by the Okanogan County Assessor.

The construction team constructed a total of 7,000 sq. ft. in greenhouse space in preparation for the 2018 planting season. Final inspection of the security system and greenhouse construction is expected to be completed in the coming weeks. Once the final inspection is approved, the licensed tenant can occupy the facility and begin cultivation.

Donald Steinberg, MCOA CEO said, “We are pleased to see the completion of the first phase of the greenhouse facilities. Once the security system is in place, we are confident the site will pass final inspection allowing our tenant-growers to occupy the facility and begin operations. MCOA continues to explore opportunities to replicate this business model and expand our real estate portfolio.”

The joint venture will lease the turnkey property to a licensed tenant, thereby acting solely as a landlord. As a turnkey landlord, the joint venture aims to provide an ideal cultivation environment for its future tenant, and it is anticipated that greenhouse will be completed by the beginning of Q3 2018. The completed 30,000 square foot cultivation facility will have a capacity of approximately 4,000 plants.

About Bougainville Ventures, Inc. 
Bougainville Venture Inc. is in the core business of converting irrigated farmland that was traditionally used to grow marginally profitable feed crops, to greenhouse-equipped farmland used to grow luxury crops with a primary focus on marijuana. Bougainville is an agricultural services company that focuses on providing growers with state-of-the-art computer controlled greenhouses and processing facilities. Bougainville offers fully built out turnkey solutions to licensed tenant-growers and luxury crop growers who will lease the facilities for production and processing. Bougainville does not “touch the plant” and only provides growing infrastructure as a landlord for licensed marijuana growers.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About BV-MCOA Management, LLC
On March 16, 2017, the Company and Bougainville Ventures, Inc. entered into a joint venture agreement that included the purchase of land in Washington State, and plans to build out facilities on the land to support leased agricultural growth, including licensed cannabis operators. As amended on November 6, 2017, the Company’s financial commitment to the joint venture was fixed at contributing $800,000, and the issuance of 15 million shares of restricted common stock to Bougainville. The Company completed its payment on November 9, 2017. The funding arranged for by the Company provided consideration for the purchase of the land and contributed to the build out of the facility. The land is pending legal transfer to the joint venture after subdivision is completed by the Okanogan County Assessor. The Company and Bougainville are currently revising and restating their joint venture agreement to resolve certain discrepancies and inconsistencies. The Company and Bougainville expect to complete this restatement shortly and once completed, the Company will disclose it on Form 8-K filed with the Securities and Exchange Commission. For more information about MCOA and BV-MCOA Management, Inc., please refer to the Company’s disclosures with the Securities and Exchange Commission (www.sec.gov).

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Namaste $N.ca Announces March 2018 Sales of C$1.24M Representing a 74% Year-on-Year Increase and Acquires 535 New Patients Representing a 142% Month-on-Month Increase $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:26 AM on Friday, April 6th, 2018

Nlogo

  • March net revenue C$1,249,670
    • 74% revenue increase in March 2018 when compared to March 2017
  • Namaste MD acquired 535 new medical cannabis patients on the NamasteMD platform
    • 142% month-over-month increase of patients
    • Company anticipates further acceleration of the growth
    • will be key driver of future revenue

VANCOUVER, British Columbia, April 06, 2018 —Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce March 2018 total unaudited net revenue as reported by the Company (including shipping revenues and after discounts and refunds) were C$1,249,670, representing a 74% revenue increase in March 2018 when compared to March 2017. Namaste’s management team is also pleased to report that the Company’s wholly owned subsidiary, Namaste MD Inc. (“NamasteMD”), has acquired 535 new medical cannabis patients on the NamasteMD platform, representing a 142% month-over-month increase of patients. NamasteMD allows patients to consult with doctors or nurse practitioners for medical cannabis in a simple and convenient platform from the comfort of their homes. The Company anticipates further acceleration of the growth in the NamasteMD patient network and expects that NamasteMD will be key driver of future revenue.

The table below display’s Namaste’s total gross sales by revenue channel.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to be seeing the positive trend of monthly sales increases year-over-year. What is most exciting is our increasing rate of patient acquisition on NamasteMD. With minimal outside marketing we were quietly able to bring on nearly 1,000 patients by the end of the March. We are working on expanding our nurse practitioner team with our partners at O Cannabis we Stand on Guard for Thee Inc. (“O Cannabis”) to accommodate the anticipated growth of patients. We strongly believe that our patients will be a key to our success, along with our strategy to provide our patients with not only the best care but also the largest and best variety of medical cannabis products. We’re proud to be innovating the industry by changing the way that patients access medical cannabis and look forward to continued growth through both the medical cannabis and hardware platforms.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales licence (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

 

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com

namastevapes.ca

everyonedoesit.ca

namastevaporizers.co.uk

everyonedoesit.co.uk

australianvaporizers.com.au

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Namaste $N.ca Announces Canada’s First Large-Scale National Prospective Observational Study to Observe the Impact of Medical #Cannabis Use for Anxiety Treatment $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:51 AM on Wednesday, April 4th, 2018

Nlogo

  • Initiated Canada’s first large-scale prospective study on a national platform called the Cannabis for Anxiety Reduction study, to determine the effectiveness of cannabis in reducing anxiety in study participants
  • One in four Canadians suffer from anxiety and the Company through this study will seek to gain valuable information from study participants on the impact of medical cannabis use in relation to their anxiety

VANCOUVER, British Columbia, April 04, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT: M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has initiated Canada’s first large-scale prospective study on a national platform called the Cannabis for Anxiety Reduction study, to determine the effectiveness of cannabis in reducing anxiety in study participants. One in four Canadians suffer from anxiety and the Company through this study will seek to gain valuable information from study participants on the impact of medical cannabis use in relation to their anxiety. Namaste is also interested in determining the safety profile of patients using medical cannabis, and whether strain and dose of medical cannabis may impact patient reductions in anxiety ratings. The study will be available to all Canadians and will be conducted under the following conditions:

  • Prospective patients must be over 25 years of age.
  • Patients must score 8 or above Hospital Anxiety and Depression Scale (HADS).
  • The study will span over a 3-month period for each registered patient.
  • The study will be submitted for approval to the Veritas Independent Review Board (IRB) prior to commencement.
  • The primary investigator in the study is a nurse practitioner.
  • Patients can self-refer into the study (without referral through a doctor or specialist).

Namaste plans to offer this study to its patients which are registered under the Company’s wholly-owned subsidiary and virtual patient platform, NamasteMD Inc. (“NamasteMD”). Patients suffering from anxiety under the terms outlined above may participate in the study. This study is the first large-scale anxiety study in the nation, establishing Namaste as an innovator in research related to anxiety and cannabis. This is also the first national study where the primary investigator is a nurse practitioner. The Company intends to conduct similar studies in various areas where patients can benefit from the use of medical cannabis. The data collected from the study is valuable for the Company as well as the industry as a whole. The study may be published in peer-reviewed research journals and other medical publications.

For more information on this study please email [email protected]

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to have initiated this study with the help of our partners at O-Cannabis. As many people in Canada suffer from varying forms of anxiety, we believe that many of these patients can benefit from the use of medical cannabis instead of prescription pharmaceutical drugs. We hope this study will provide very valuable information for Namaste and for the industry. We encourage qualifying patients to participate and look forward to seeing the results. We plan to undertake additional studies to bring awareness and a better understanding of how medical cannabis can benefit Canadians. We believe that these studies will help Namaste by attracting a larger base of patients and help solidify Namaste’s position as a leader in the Canadian medical cannabis industry.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.